Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.85% | 18.75% | -11.75% | -19.37% | -18.59% |
| Total Depreciation and Amortization | 19.14% | 39.04% | 46.93% | 38.84% | 103.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.18% | 53.02% | 48.70% | 23.00% | 18.70% |
| Change in Net Operating Assets | -104.68% | -32.26% | -97.36% | -0.87% | -49.22% |
| Cash from Operations | 12.23% | 29.09% | -19.47% | -14.35% | -40.38% |
| Capital Expenditure | 73.52% | 9.10% | -259.85% | 92.88% | 28.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.68% | -59.94% | 122.69% | 189.15% | -29.73% |
| Cash from Investing | 49.35% | -63.08% | 122.09% | 228.44% | -29.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -98.73% | -100.00% |
| Repurchase of Common Stock | 70.32% | 90.23% | 80.98% | -107.23% | 50.12% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 70.32% | 92.22% | -100.08% | -99.42% | 67.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 269.54% | -130.43% | -87.18% | 94.18% | -158.37% |